A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF KARXT + KARX-EC FOR THE TREATMENT OF COGNITIVE IMPAIRMENT ASSOCIATED WITH MILD TO MODERATE ALZHEIMER¿S DISEASE (MINDSET 1)

Intervention/treatment:
XANOMELINE-TROSPIUM (KARXT) / XANOMELINE
Medical condition:
ALZHEIMER'S DISEASE
Protocol code:
CN0120051
Control number:
299419
Status:
Recruiting
Approved:
August 01, 2025
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT06976216
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
60 Years to 85 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Role
CONTACT
Phone:
855-907-3286
Name
First line of the email MUST contain NCT # and Site #.
Role
CONTACT
Sponsor
BRISTOL-MYERS SQUIBB CANADA

Locations

ALPHA Recherche Clinique
Québec, G3K 2P8
Recruiting
Name
Claude Patry, Site 0264
Role
CONTACT
Phone:
418-847-1112

British Columbia

OCT Research ULC
Kelowna, British Columbia, V1Y 1Z9
Recruiting
Name
Pieter Strauss, Site 0233
Role
CONTACT
Phone:
250-862-8141
Richmond Clinical Trials
Richmond, British Columbia, V6V 2L1
Recruiting
Name
Harris Lari, Site 0234
Role
CONTACT
Phone:
604-373-4954

Nova Scotia

Centricity Research Halifax Multispecialty
Halifax, Nova Scotia, B3S 1N2
Recruiting
Name
Kerrie Schoffer, Site 0236
Role
CONTACT
Phone:
902-609-6845 x7115

Ontario

Ottawa Memory Clinic
Ottawa, Ontario, K1Z 1G3
Recruiting
Name
Richard Bergeron, Site 0237
Role
CONTACT
Phone:
1-613-702-1000
Toronto Memory Program
Toronto, Ontario, M3B 2S7
Recruiting
Name
Manpreet Kaur, Site 0235
Role
CONTACT
Phone:
416-386-9606

Quebec

Diex Recherche Victoriaville
Victoriaville, Quebec, G6P 3Z8
Recruiting
Name
Ethel Bellavance, Site 0239
Role
CONTACT
Phone:
819-260-1172
MoCA Research and Innovation Inc.
Greenfield Park, Quebec, J4V 2J2
Recruiting
Name
Ziad Nasreddine, Site 0238
Role
CONTACT
Phone:
450-672-7766
Did you find what you were looking for?

Contacts and resources